Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer

Pharmaceutical Development and Technology

Volumn 17, Issue 5, 2012, Pages 521-540

  Krishnaiah, Yellela S R ^a   Khan, Mansoor A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Colon specific drug delivery; Colorectal cancer; Oral; Prevention; Targeted; Treatment

Indexed keywords

9 AMINOCAMPTOTHECIN; ACETYLSALICYLIC ACID; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; EUDRAGIT; EUDRAGIT P 4135F; EUDRAGIT RS; FLUOROURACIL; FOLINIC ACID; INDOMETACIN; IRINOTECAN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PANITUMUMAB; RESVERATROL; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

BLOOD TOXICITY; CANCER PREVENTION; CANCER STAGING; CANCER SURGERY; COLON ADENOMA; COLON CANCER; COLON FLORA; COLON TUMOR; COLORECTAL CANCER; COLORECTAL POLYP; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INTESTINE TRANSIT TIME; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; STOMACH ULCER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS; COLON; COLORECTAL NEOPLASMS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 84865317499     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2012.696268     Document Type: Review

References (225)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
3. Nguyen HL, Hwang J. Treatment of metastatic colorectal cancer in the elderly. Curr Treat Options Oncol 2009;10:287-295.
4. Marshall JR. Prevention of colorectal cancer: Diet, chemoprevention, and lifestyle. Gastroenterol Clin North Am 2008;37:73-82, vi.
5. Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S, Couture J. Molecular biology of colorectal cancer. Curr Probl Cancer 1997;21:233-300.
6. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011;60:116-129.
7. Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF et al. Chemoprevention of colorectal cancer: Systematic review and economic evaluation. Health Technol Assess 2010;14: 1-206.
8. Potter JD. Colorectal cancer: Molecules and populations. J Natl Cancer Inst 1999;91:916-932. (Pubitemid 29272518)
9. Haggar FA, Boushey RP. Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009;22:191-197.
10. Rubin DT. An updated approach to dysplasia in IBD. J Gastrointest Surg 2008;12:2153-2156.
11. Lyakhovich A, Gasche C. Systematic review: Molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 2010;31:202-209.
12. Ades S. Adjuvant chemotherapy for colon cancer in the elderly: Moving from evidence to practice. Oncology (Williston Park, NY) 2009;23:162-167.
13. Son HS, Lee WY, Lee WS, Yun SH, Chun HK. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Med J 2009;50:796-802.
14. Jay M, Beihn RM, Digenis GA, Deland FH, Caldwell L, Mlodozeniec AR. Disposition of radiolabelled suppositories in humans. J Pharm Pharmacol 1985;37:266-268. (Pubitemid 15149841)
15. Hardy JG. (1989). Colonic transit and drug delivery. In: Hardy JG, Davis SS, Wilson CG, eds. Drug Delivery to the Gastrointestinal Tract. Chichester: Ellis Horwood, 75-81.
16. Wood E, Wilson CG, Hardy JG. The spreading of foam and solution enemas. Int J Pharm 1985;25:191-197. (Pubitemid 15044953)
17. Friend DR. New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005;57:247-265. (Pubitemid 39536101)
18. McConnell EL, Liu F, Basit AW. Colonic treatments and targets: Issues and opportunities. J Drug Target 2009;17:335-363.
19. Krishnaiah YSR, Satyanarayana V, Dinesh Kumar B, Karthikeyan RS, Bhaskar P. In vivo pharmacokinetics in human volunteers: Oral administered guar gum-based colon-targeted 5-fluorouracil tablets. Eur J Pharm Sci 2003;19:355-362. (Pubitemid 36952397)
20. Reis ED, Vine AJ, Heimann T. Radiation damage to the rectum and anus: Pathophysiology, clinical features and surgical implications. Colorectal Dis 2002;4:2-12. (Pubitemid 34285249)
21. Robertson JM. The role of radiation therapy for colorectal cancer. Gastroenterol Clin North Am 2008;37:269-85, ix. (Pubitemid 351289028)
22. Pohl A, Zhang W, Ning Y, Manegold PC, Lurje G, Lenz HJ. Targeting metastatic colorectal cancer in 2008: A long way from 5-FU. Oncology (Williston Park, NY) 2008;22:456-62; discussion 462.
23. Piedbois P, Buyse M, Rustum Y, Machover D, Erlichman C, Carlson RW et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal-cancer -evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
24. Wohlhueter RM, McIvor RS, Plagemann PG. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol 1980;104:309-319. (Pubitemid 11127508)
25. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med 2009;60:207-219.
26. Sabharwal A, Kerr D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: Past, present and future. Expert Rev Anticancer Ther 2007;7:477-487. (Pubitemid 46681804)
27. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005;31:90-105. (Pubitemid 40542888)
28. Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P. Sequence-and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 1998;54:770-777. (Pubitemid 28523169)
29. Robert J, Rivory L. Pharmacology of irinotecan. Drugs Today 1998;34:777-803. (Pubitemid 28508850)
30. Chabot GG. Clinical pharmacology and pharmacodynamics of irinotecan. A review. Ann N Y Acad Sci 1996;803:164-172. (Pubitemid 27057983)
31. Aprile G, Mazzer M, Moroso S, Puglisi F. Pharmacology and therapeutic efficacy of capecitabine: Focus on breast and colorectal cancer. Anticancer Drugs 2009;20:217-229.
32. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947. (Pubitemid 30644117)
33. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, Diasio RB et al. The continuum of care: A paradigm for the management of metastatic colorectal cancer. Oncologist 2007;12:38-50. (Pubitemid 46143501)
34. Lea A, Allingham-Hawkins D, Levine S. BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer. PLoS Curr 2010;2:RRN1187.
35. Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 2010;39:601-613.
36. Ortega J, Vigil CE, Chodkiewicz C. Current progress in targeted therapy for colorectal cancer. Cancer Control 2010;17:7-15.
37. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-680. (Pubitemid 40216420)
38. Saadeh CE, Lee HS. Panitumumab: A fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother 2007;41:606-613. (Pubitemid 46625483)
39. Frieze DA, McCune JS. Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother 2006;40:241-250. (Pubitemid 43269854)
40. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1-20.
41. Shiff SJ, Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: Evolving concepts of their chemopreventive actions. Gastroenterology 1997;113:1992-1998. (Pubitemid 27512159)
42. Ruschoff J, Wallinger S, Dietmaier W, Bocker T, Brockhoff G, Hofstadter F et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA 1998;95:11301-11306. (Pubitemid 28450123)
43. Bleiberg H. Colorectal cancer: A clinical guide to therapy. London: Martin Dunitz; 2002.
44. Courtney ED, Melville DM, Leicester RJ. Review article: Chemoprevention of colorectal cancer. Aliment Pharmacol Ther 2004;19:1-24. (Pubitemid 38125634)
45. Takayama T, Goji T, Taniguchi T, Inoue A. Chemoprevention of colorectal cancer-experimental and clinical aspects-. J Med Invest 2009;56:1-5.
46. Krishnaiah YSR, Satyanarayana V, Kumar BD, Karthikeyan RS. Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer. J Drug Target 2002;10:247-254. (Pubitemid 34467294)
47. Krishnaiah YSR, Satyanarayana V, Dinesh Kumar B, Karthikeyan RS, Bhaskar P. In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human olunteers. Eur J Drug Metab Pharmacokinet 2002;27:273-280. (Pubitemid 36205475)
48. Thakral NK, Ray AR, Majumdar DK. Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer. J Mater Sci Mater Med 2010;21:2691-2699.
49. Elias EJ, Anil S, Ahmad S, Daud A. Colon targeted curcumin delivery using guar gum. Nat Prod Commun 2010;5: 915-918.
50. Das S, Ng KY. Impact of glutaraldehyde on in vivo colonspecific release of resveratrol from biodegradable pectin-based formulation. J Pharm Sci 2010;99:4903-4916.
51. Manconi M, Mura S, Manca ML, Fadda AM, Dolz M, Hernandez MJ et al. Chitosomes as drug delivery systems for C-phycocyanin: Preparation and characterization. Int J Pharm 2010;392:92-100.
52. Patel MM, Amin AF. Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer. Drug Deliv 2011;18:281-293.
53. Markowitz SD, Dawson DM, Willis J, Willson JK. Focus on colon cancer. Cancer Cell 2002;1:233-236. (Pubitemid 41039147)
54. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009;361: 2449-2460.
55. Skibber J, Minsky B, Hoff P. (2001). Cancer of the colon. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams and Wilkins, 1216-1271.
56. Mrsny RJ. The colon as a site for drug delivery. J Contr Release 1992;22:15-34.
57. Tannergren C, Bergendal A, Lennernas H, Abrahamsson B. Toward an increased understanding of the barriers to colonic drug absorption in humans: Implications for early controlled release candidate assessment. Mol Pharm 2009;6:60-73.
58. Tozaki H, Emi Y, Horisaka E, Fujita T, Yamamoto A, Muranishi S. Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: Implications in peptide delivery to the colon. J Pharm Pharmacol 1997;49:164-168. (Pubitemid 27096110)
59. Katsuma M, Watanabe S, Kawai H, Takemura S, Sako K. Effects of absorption promoters on insulin absorption through colontargeted delivery. Int J Pharm 2006;307:156-162. (Pubitemid 41820408)
60. Basan H, Gumusderelioglu M, Tevfik Orbey M. Release characteristics of salmon calcitonin from dextran hydrogels for colon-specific delivery. Eur J Pharm Biopharm 2007;65:39-46. (Pubitemid 44827694)
61. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review. Oncologist 2002;7:288-323. (Pubitemid 34919955)
62. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-338. (Pubitemid 37328853)
63. Queener SF, Morris HP, Weber G. Dihydrouracil dehydrogenase activity in normal, differentiating and regnerating liver and in hepatomas. Cancer Res 1971;31:1004-1009.
64. Pitot HC, Heidelberger C. Metabolic regulatory circuits and carcinogenesis. Cancer Res 1963;23:1694-1700.
65. Ho DH, Townsend L, Luna MA, Bodey GP. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 1986;6:781-784. (Pubitemid 16032818)
66. Wei H, Qing D, De-Ying C, Bai X, Li-Fang F. In-vitro and in-vivo studies of pectin/ethylcellulosefilm-coated pellets of 5-fluorouracil for colonic targeting. J Pharm Pharmacol 2008;60:35-44.
67. Rivory LP. New drugs for colorectal cancer-mechanisms of action. Aust Prescr 2002;25:108-110.
68. Tubic-Grozdanis M, Hilfinger JM, Amidon GL, Kim JS, Kijek P, Staubach P et al. Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm Res 2008;25:1591-1600.
69. Rahman Z, Kohli K, Zhang SQ, Khar RK, Ali M, Charoo NA et al. In-vivo evaluation in rats of colon-specific microspheres containing 5-fluorouracil. J Pharm Pharmacol 2008;60:615-623. (Pubitemid 351589049)
70. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Microsphere design for the colonic delivery of 5-fluorouracil. J Control Release 2003;90:313-322. (Pubitemid 36859963)
71. Sinha VR, Mittal BR, Bhutani KK, Kumria R. Colonic drug delivery of 5-fluorouracil: An in vitro evaluation. Int J Pharm 2004;269:101-108. (Pubitemid 38032827)
72. Sinha VR, Mittal BR, Kumria R. In vivo evaluation of time and site of disintegration of polysaccharide tablet prepared for colonspecific drug delivery. Int J Pharm 2005;289:79-85. (Pubitemid 40093543)
73. Xu C, Zhang JS, Mo Y, Tan RX. Calcium pectinate capsules for colon-specific drug delivery. Drug Dev Ind Pharm 2005;31: 127-134. (Pubitemid 40315708)
74. Zambito Y, Baggiani A, Carelli V, Serafini MF, Di Colo G. Matrices for site-specific controlled-delivery of 5-fluorouracil to descending colon. J Control Release 2005;102:669-677. (Pubitemid 40170209)
75. Paharia A, Yadav AK, Rai G, Jain SK, Pancholi SS, Agrawal GP. Eudragit-coated pectin microspheres of 5-fluorouracil for colon targeting. AAPS PharmSciTech 2007;8:12.
76. Sinha VR, Singh A, Singh S, Bhinge JR. Compression coated systems for colonic delivery of 5-fluorouracil. J Pharm Pharmacol 2007;59:359-365. (Pubitemid 47050899)
77. Mei QB, Wang QW, Liu XY, Liu L, Feng J, Li YH, Guo ZJ. Synthesis and evaluation of the 5-fluorouracil-pectin conjugate targeted at the colon. Med Chem Res 2007;16:370-379.
78. Wei H, Qing D, De-Ying C, Bai X, Li-Fang F. Pectin/Ethylcellulose as film coatings for colon-specific drug delivery: Preparation and in vitro evaluation using 5-fluorouracil pellets. PDA J Pharm Sci Technol 2007;61:121-130. (Pubitemid 46651444)
79. Wei H, Qing D, De-Ying C, Bai X, Li-Fang F. Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats. Int J Pharm 2008;348:35-45.
80. Li S, Wang A, Jiang W, Guan Z. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer 2008;8:103.
81. Sahoo PK, Ray D, Mohapatra DK, Mohapatra RK, Mohanta GP. Synthesis and colon-specific drug delivery of a poly(acrylic acidco-acrylamide)/MBA nanosized hydrogel. J Biomat Sci-Polym E 2008;19:1487-1502.
82. Glavas Dodov M, Calis S, Crcarevska MS, Geskovski N, Petrovska V, Goracinova K. Wheat germ agglutinin-conjugated chitosan-Caalginate microparticles for local colon delivery of 5-FU: Development and in vitro characterization. Int J Pharm 2009;381:166-175.
83. Ji CM, Xu HN, Wu W. Guar gum as potential film coating material for colon-specific delivery of fluorouracil. J Biomater Appl 2009;23:311-329.
84. Mishra PK, Gulbake A, Jain A, Vyas SP, Jain SK. Targeted delivery of an anti-cancer agent via steroid coupled liposomes. Drug Deliv 2009;16:437-447.
85. Rahman Z, Kohli K, Khar RK, Ali M, Charoo NA, Shamsher AA. Characterization of 5-fluorouracil microspheres for colonic delivery. AAPS PharmSciTech 2006;7:E47.
86. Amorij JP, Westra TA, Hinrichs WL, Huckriede A, Frijlink HW. Towards an oral influenza vaccine: Comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model. Vaccine 2007;26:67-76. (Pubitemid 350213207)
87. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update. Adv Drug Deliv Rev 2008;60:702-716.
88. McConnell EL, Basit AW, Murdan S. The colon as a target for vaccination: Quantification of lymphoid tissue in mouse colon prior to vaccination. J Pharm Pharmacol 2006;58:A46-A46.
89. Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 2003;18:3-18. (Pubitemid 36120550)
90. Rubinstein A. Colonic drug delivery. Drug Discov Today Tech 2005;2:33-37. (Pubitemid 40946306)
91. Van den Mooter G. Colon drug delivery. Expert Opin Drug Deliv 2006;3:111-125.
92. McConnell EL, Short MD, Basit AW. An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. J Control Release 2008;130:154-160.
93. Makhlof A, Tozuka Y, Takeuchi H. pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur J Pharm Biopharm 2009;72:1-8.
94. Gao C, Huang J, Jiao Y, Shan L, Liu Y, Li Y et al. In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit FS 30 D-coated pellets. Int J Pharm 2006;322:104-112. (Pubitemid 44331530)
95. McConnell EL, Fadda HM, Basit AW. Gut instincts: Explorations in intestinal physiology and drug delivery. Int J Pharm 2008;364:213-226.
96. Friend DR. Colon-specific drug delivery. Adv Drug Deliver Rev 1991;7:149-199.
97. Ovesen L, Bendtsen F, Tage-Jensen U, Pedersen NT, Gram BR, Rune SJ. Intraluminal pH in the stomach, duodenum, and proximal jejunum in normal subjects and patients with exocrine pancreatic insufficiency. Gastroenterology 1986;90:958-962. (Pubitemid 16124773)
98. Watson BW, Meldrum SJ, Riddle HC, Brown RL, Sladen GE. pH profile of gut as measured by radiotelemetry capsule. Br Med J 1972;2:104-106.
99. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988;29:1035-1041.
100. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001;48:571-577. (Pubitemid 32234805)
101. Fallingborg J, Pedersen P, Jacobsen BA. Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease. Dig Dis Sci 1998;43:702-705. (Pubitemid 28176455)
102. Sasaki Y, Hada R, Nakajima H, Fukuda S, Munakata A. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: Colonic luminal pH in normal subjects and patients with Crohn's disease. Am J Gastroenterol 1997;92:114-118. (Pubitemid 27027040)
103. Maroni A, Del Curto MD, Serratoni M, Zema L, Foppoli A, Gazzaniga A et al. Feasibility, stability and release performance of a time-dependent insulin delivery system intended for oral colon release. Eur J Pharm Biopharm 2009;72:246-251.
104. Varum FJ, Merchant HA, Basit AW. Oral modified-release formulations in motion: The relationship between gastrointestinal transit and drug absorption. Int J Pharm 2010;395:26-36.
105. Yuen KH. The transit of dosage forms through the small intestine. Int J Pharm 2010;395:9-16.
106. Kimura T, Higaki K. Gastrointestinal transit and drug absorption. Biol Pharm Bull 2002;25:149-164. (Pubitemid 39592096)
107. Davis SS, Hardy JG, Taylor MJ, Stockwell A, Whalley DR, Wilson CG. The in-vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy. J Pharm Pharmacol 1984;36:740-742. (Pubitemid 14021954)
108. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986;27:886-892. (Pubitemid 16044258)
109. Barrow L, Spiller RC, Wilson CG. Pathological influences on colonic motility -implications for drug delivery. Adv Drug Deliver Rev 1991;7:201-218.
110. Hardy JG, Davis SS, Khosla R, Robertson CS. Gastrointestinal transit of small tablets in patients with ulcerative colitis. Int J Pharm 1988;48:79-82.
111. Adkin DA, Davis SS, Sparrow RA, Wilding IR. Colonic transit of different sized tablets in healthy-subjects. J Contr Release 1993;23:147-156. (Pubitemid 23037817)
112. Hardy JG, Wilson CG, Wood E. Drug delivery to the proximal colon. J Pharm Pharmacol 1985;37:874-877. (Pubitemid 16222321)
113. Basit AW, Short MD, McConnell EL. Microbiota-triggered colonic delivery: Robustness of the polysaccharide approach in the fed state in man. J Drug Target 2009;17:64-71.
114. Haeberlin B, Friend DR. (1992). Anatomy and physiology of the gastrointestinal tract. In: Friend DR, ed. Oral Colon-Specific Drug Delivery. Boca Raton: CRC Press, 1-43.
115. Hebden JM, Blackshaw PE, Perkins AC, Wilson CG, Spiller RC. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2000;14:155-161. (Pubitemid 30088291)
116. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology 1984;86:174-193. (Pubitemid 14177335)
117. Chourasia MK, Jain SK. Polysaccharides for colon targeted drug delivery. Drug Deliv 2004;11:129-148. (Pubitemid 38437082)
118. Krishnaiah YSR, Satyanarayana S. (2001). Colon-specific drug delivery systems. In: Jain NK, ed. Advances in Controlled and Novel Drug Delivery. New Delhi: CBS Publishers and Distributors, 89-119.
119. Rubinstein A. Natural polysaccharides as targeting tools of drugs to the human colon. Drug Develop Res 2000;50:435-439.
120. Vandamme TF, Lenourry A, Charrueau C, Chaumeil J. The use of polysaccharides to target drugs to the colon. Carbohyd Polym 2002;48:219-231. (Pubitemid 34141159)
121. Drasar BS, Hill J. (1974). Human intestinal flora. London: Academic Press.
122. Simon GL, Gorbach SL. (1983). Bacteriology of the colon. In: Bustos-Fernandez L, ed. Colon, Structure and Function. New York: Plenum Press, 103-114.
123. Scheline RR. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 1973;25:451-523.
124. Peppercorn MA, Goldman P. Caffeic acid metabolism by gnotobiotic rats and their intestinal bacteria. Proc Natl Acad Sci USA 1972;69:1413-1415.
125. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972;181:555-562.
126. Goldman P, Peppercorn MA, Goldin BR. Metabolism of drugs by microorganisms in the intestine. Am J Clin Nutr 1974;27:1348-1355.
127. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. N Engl J Med 1981;305:789-794. (Pubitemid 11007233)
128. Rowland IR. Factors affecting metabolic activity of the intestinal microflora. Drug Metab Rev 1988;19:243-261. (Pubitemid 19043736)
129. Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: Current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl 2001;36:29-40. (Pubitemid 33070909)
130. Faigle JW. (1993). Drug metabolism in the colon wall and lumen. In: Beick PR, ed. Colonic Drug Absorption and Metabolism. New York: Marcel Dekker Inc, 29-54.
131. Powell DW. Barrier function of epithelia. Am J Physiol 1981;241:G275-G288.
132. Krishnaiah YSR. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Bioavail 2010;2:28-36.
133. Fix JA, Engle K, Porter PA, Leppert PS, Selk SJ, Gardner CR et al. Acylcarnitines: Drug absorption-enhancing agents in the gastrointestinal tract. Am J Physiol 1986;251:G332-G340.
134. Muranishi S. Absorption enhancers. Crit Rev Ther Drug Carrier Syst 1990;7:1-33. (Pubitemid 20355576)
135. Yanez JA, Wang SW, Knemeyer IW, Wirth MA, Alton KB. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev 2011;63:923-942.
136. Garzon-Aburbeh A, Poupaert JH, Claesen M, Dumont P, Atassi G. 1,3-dipalmitoylglycerol ester of chlorambucil as a lymphotropic, orally administrable antineoplastic agent. J Med Chem 1983;26:1200-1203. (Pubitemid 13037374)
137. Muranishi S. [Lymphatic delivery of drugs and its application to cancer chemotherapy (author's transl)]. Yakugaku Zasshi 1980;100:687-698. (Pubitemid 11248764)
138. Basit AW. Advances in colonic drug delivery. Drugs 2005;65: 1991-2007. (Pubitemid 41324059)
139. Rama Prasad YV, Krishnaiah YSR, Satyanarayana S. Trends in colonoic drug delivery: A review. Indian Drugs 1996;33:1-10. (Pubitemid 26248119)
140. Reddy SM, Sinha VR, Reddy DS. Novel oral colon-specific drug delivery systems for pharmacotherapy of peptide and nonpeptide drugs. Drugs Today 1999;35:537-580. (Pubitemid 29422129)
141. Kinget R, Kalala W, Vervoort L, van den Mooter G. Colonic drug targeting. J Drug Target 1998;6:129-149. (Pubitemid 29033981)
142. Ji C, Xu H, Wu W. In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS30D-coated colon-targeted pellets of indomethacin. J Drug Target 2007;15:123-131. (Pubitemid 46957698)
143. Rudolph MW, Klein S, Beckert TE, Petereit H, Dressman JB. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm 2001;51:183-190. (Pubitemid 32422095)
144. Leopold CS. Coated dosage forms for colon-specific drug delivery. Pharm Sci Technol Today 1999;2:197-204. (Pubitemid 29238363)
145. Leopold CS, Eikeler D. Basic coating polymers for the colonspecific drug delivery in inflammatory bowel disease. Drug Dev Ind Pharm 2000;26:1239-1246. (Pubitemid 32037420)
146. Rashid A. Dispensing device. European Patent: 0384642; 1990.
147. Marvola M, Aito H, Pohto P, Kannikoski A, Nykanen S, Kokkonen P. Gastrointestinal transit and concomitant absorption of verapamil from a single-unit sustained-release tablet. Drug Dev Ind Pharm 1987;13:1593-1609.
148. Patel MM, Shah TJ, Amin AF, Shah NN. Design, development and optimization of a novel time and pH-dependent colon targeted drug delivery system. Pharm Dev Technol 2009;14:62-69.
149. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-895.
150. Van den Mooter G, Samyn C, Kinget R. Azo polymers for colonspecific drug delivery. II: Influence of the type of azo polymer on the degradation by intestinal microflora. Int J Pharm 1993;97:133-139. (Pubitemid 23242374)
151. Kalala W, Kinget R, Van den Mooter G, Samyn C. Colonic drugtargeting: In vitro release of ibuprofen from capsules coated with poly(ether-ester) azopolymers. Int J Pharm 1996;139:187-195. (Pubitemid 26276281)
152. Tozaki H, Fujita T, Komoike J, Kim SI, Terashima H, Muranishi S et al. Colon-specific delivery of budesonide with azopolymer-coated pellets: Therapeutic effects of budesonide with a novel dosage form against 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats. J Pharm Pharmacol 1999;51:257-261. (Pubitemid 29192778)
153. Wong TW, Colombo G, Sonvico F. Pectin matrix as oral drug delivery vehicle for colon cancer treatment. AAPS PharmSciTech 2011;12:201-214.
154. Lai JY, Wang LQ, Tu K, Qian XQ, Zhan SL. Synthesis and characterization of azo-containing dextran hydrogels as carriers for colonic drug targeting. Rare Metal Mat Eng 2008;37:595-598.
155. Basak P, Adhikari B. Poly (vinyl alcohol) hydrogels for pH dependent colon targeted drug delivery. J Mater Sci Mater Med 2009;20 Suppl 1:S137-S146.
156. Mahkam M. New pH-sensitive glycopolymers for colon-specific drug delivery. Drug Deliv 2007;14:147-153. (Pubitemid 46650786)
157. Davaran S, Rashidi MR, Khani A. Synthesis of chemically crosslinked hydroxypropyl methyl cellulose hydrogels and their application in controlled release of 5-amino salicylic acid. Drug Dev Ind Pharm 2007;33:881-887. (Pubitemid 47345861)
158. Saboktakin MR, Tabatabaie R, Maharramov A, Ramazanov MA. Synthesis and characterization of superparamagnetic chitosandextran sulfate hydrogels as nano carriers for colon-specific drug delivery. Carbohyd Polym 2010;81:372-376.
159. Jain SK, Jain A, Gupta Y, Jain A, Khare P, Kannandasan M. Targeted delivery of 5-ASA to colon using chitosan hydrogel microspheres. J Drug Deliv Sci Tec 2008;18:315-321.
160. Singh B, Sharma N, Chauhan N. Synthesis, characterization and swelling studies of pH responsive psyllium and methacrylamide based hydrogels for the use in colon specific drug delivery. Carbohyd Polym 2007;69:631-643. (Pubitemid 46776840)
161. Salyers AA, Vercellotti JR, West SE, Wilkins TD. Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol 1977;33:319-322. (Pubitemid 8099781)
162. Hovgaard L, Brondsted H. Current applications of polysaccharides in colon targeting. Crit Rev Ther Drug Carrier Syst 1996;13:185-223. (Pubitemid 27024257)
163. Englyst HN, Hay S, Macfarlane GT. Polysaccharide breakdown by mixed populations of human fecal bacteria. Fems Microbiol Ecol 1987;45:163-171.
164. Shah N, Shah T, Amin A. Polysaccharides: A targeting strategy for colonic drug delivery. Expert Opin Drug Deliv 2011;8: 779-796.
165. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: New approaches and in vitro/in vivo evaluation. Int J Pharm 2002; 235:1-15. (Pubitemid 34185432)
166. Muraoka M, Hu Z, Shimokawa T, Sekino S, Kurogoshi R, Kuboi Y et al. Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. J Control Release 1998;52:119-129. (Pubitemid 28123179)
167. Niwa K, Takaya T, Morimoto T, Takada K. Preparation and evaluation of a time-controlled release capsule made of ethylcellulose for colon delivery of drugs. J Drug Target 1995;3:83-89.
168. Hu Z, Kimura G, Mawatari S, Shimokawa T, Yoshikawa Y, Takada K. New preparation method of intestinal pressure-controlled colon delivery capsules by coating machine and evaluation in beagle dogs. J Control Release 1998;56:293-302. (Pubitemid 28511149)
169. Barakat NS, Al-Suwayeh SA, Taha EI, Bakry Yassin AE. A new pressure-controlled colon delivery capsule for chronotherapeutic treatment of nocturnal asthma. J Drug Target 2011;19:365-372.
170. Gazzaniga A, Maroni A, Sangalli ME, Zema L. Time-controlled oral delivery systems for colon targeting. Expert Opin Drug Deliv 2006;3:583-597. (Pubitemid 44383487)
171. Schoffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 2004;15:85-106. (Pubitemid 38316741)
172. Hahn RG, Moertel CG, Schutt AJ, Bruckner HW. A doubleblind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. Cancer 1975;35:1031-1035.
173. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-237. (Pubitemid 19114713)
174. Puoci F, Iemma F, Cirillo G, Picci N, Matricardi P, Alhaiqu F. Molecularly imprinted polymers for 5-fluorouracil release in biological fluids. Molecules 2007;12:805-814.
175. Krishnaiah YSR, Satyanarayana V, Dinesh Kumar B, Karthikeyan RS. In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. Eur J Pharm Sci 2002;16:185-192. (Pubitemid 34786453)
176. Rubinstein A, Radai R, Ezra M, Pathak S, Rokem JS. In vitro evaluation of calcium pectinate: A potential colon-specific drug delivery carrier. Pharm Res 1993;10:258-263. (Pubitemid 23041741)
177. Adkin DA, Kenyon CJ, Lerner EI, Landau I, Strauss E, Caron D et al. The use of scintigraphy to provide "proof of concept" for novel polysaccharide preparations designed for colonic drug delivery. Pharm Res 1997;14:103-107. (Pubitemid 27113323)
178. Ashford M, Fell J, Attwood D, Sharma H, Woodhead P. An evaluation of pectin as a carrier for drug targeting to the colon. J Contr Release 1993;26:213-220. (Pubitemid 23287366)
179. Ashford M, Fell J, Attwood D, Sharma H, Woodhead P. Studies on pectin formulations for colonic drug delivery. J Contr Release 1994;30:225-232. (Pubitemid 24216836)
180. Jain A, Gupta Y, Jain SK. Potential of calcium pectinate beads for target
181. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Observations in simultaneous microencapsulation of 5-fluorouracil and leucovorin for combined pH-dependent release. Eur J Pharm Biopharm 2005;59:367-371. (Pubitemid 40127594)
182. Singh B, Chauhan N, Kumar S. Radiation crosslinked psyllium and polyacrylic acid based hydrogels for use in colon specific drug delivery. Carbohyd Polym 2008;73:446-455.
183. Jain SK, Jain A. In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur J Pharm Sci 2008;35:404-416.
184. Jain SK, Jain A, Ganesh N, Barve J, Beg AM. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomed-Nanotechnol 2010;6:179-190.
185. McLeod HL, Douglas F, Oates M, Symonds RP, Prakash D, van der Zee AG et al. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 1994;59:607-611. (Pubitemid 24358582)
186. Takimoto CH. Why drugs fail: Of mice and men revisited. Clin Cancer Res 2001;7:229-230. (Pubitemid 32183023)
187. Gerrits CJ, de Jonge MJ, Schellens JH, Stoter G, Verweij J. Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development. Br J Cancer 1997; 76:952-962. (Pubitemid 27401951)
188. Kirstein MN, Houghton PJ, Cheshire PJ, Richmond LB, Smith AK, Hanna SK et al. Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 2001;7:358-366. (Pubitemid 32183040)
189. Gao SQ, Sun Y, Kopeckova P, Peterson CM, Kopecek J. Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenografts. Macromol Biosci 2009;9:1135-1142.
190. Sakuma S, Lu ZR, Kopeckova P, Kopecek J. Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin. J Control Release 2001;75:365-379. (Pubitemid 32727266)
191. Gao SQ, Lu ZR, Petri B, Kopeckova P, Kopecek J. Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a1,6-elimination spacer. J Control Release 2006;110:323-331. (Pubitemid 41827485)
192. Gao SQ, Lu ZR, Kopeckova P, Kopecek J. Biodistribution and pharmacokinetics of colon-specific HPMA copolymer-9-aminocamptothecin conjugate in mice. J Control Release 2007;117:179-185. (Pubitemid 46161874)
193. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-1619. (Pubitemid 24007679)
194. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-1899. (Pubitemid 29272670)
195. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-809. (Pubitemid 26404280)
196. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-412. (Pubitemid 28087398)
197. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-1968. (Pubitemid 30419092)
198. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952. (Pubitemid 30419089)
199. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293-297. (Pubitemid 30070754)
200. Geis GS. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect? J Rheumatol Suppl 1999;56:31-36. (Pubitemid 29183024)
201. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al.; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080. (Pubitemid 40365348)
202. Cotter J, Wooltorton E. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ 2005; 172:1299. (Pubitemid 40745070)
203. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102. (Pubitemid 40365350)
204. Rubinstein A, Haupt S, Zioni T, Gati I, Kleinstern J. Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. Eur J Pharm Sci 2006;28:204-211. (Pubitemid 43766100)
205. Al-Saidan SM, Krishnaiah YSR, Satyanarayana V, Rao GS. In vitro and in vivo evaluation of guar gum-based matrix tablets of rofecoxib for colonic drug delivery. Curr Drug Deliv 2005;2:155-163. (Pubitemid 40488625)
206. Sinha VR, Bhinge JR, Kumria R, Kumar M. Development of pulsatile systems for targeted drug delivery of celecoxib for prophylaxis of colorectal cancer. Drug Deliv 2006;13:221-225.
207. Majumdar DK, Thakral NK, Ray AR, Bar-Shalom D, Eriksson AH. The quest for targeted delivery in colon cancer: Mucoadhesive valdecoxib microspheres. Int J Nanomed 2011; 6:1057-1068.
208. Chu EC, Chai J, Tarnawski AS. NSAIDs activate PTEN and other phosphatases in human colon cancer cells: Novel mechanism for chemopreventive action of NSAIDs. Biochem Biophys Res Commun 2004;320:875-879. (Pubitemid 38887224)
209. Cai X, Yang L, Zhang LM, Wu Q. Synthesis and anaerobic biodegradation of indomethacin-conjugated cellulose ethers used for colon-specific drug delivery. Bioresour Technol 2009;100:4164-4170.
210. Asghar LF, Chure CB, Chandran S. Colon specific delivery of indomethacin: Effect of incorporating pH sensitive polymers in xanthan gum matrix bases. AAPS PharmSciTech 2009; 10:418-429.
211. Prabhu S, Kanthamneni N, Chaudhary A, Wang J. Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer. Int J Oncol 2010;37:177-185.
212. Martin AR, Villegas I, La Casa C, de la Lastra CA. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 2004;67:1399-1410. (Pubitemid 38315105)
213. Martin AR, Villegas I, Sanchez-Hidalgo M, de la Lastra CA. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 2006;147:873-885.
214. Das S, Lin HS, Ho PC, Ng KY. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res 2008;25:2593-2600.
215. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR et al. Cancer prevention with natural compounds. Semin Oncol 2010;37:258-281.
216. Reddy MC, Subhashini J, Mahipal SV, Bhat VB, Srinivas Reddy P, Kiranmai G et al. C-Phycocyanin, a selective cyclooxygenase-2 inhibitor, induces apoptosis in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem Biophys Res Commun 2003;304:385-392. (Pubitemid 36444582)
217. Lichtenstein GR, Kamm MA. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis-methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther 2008;28:663-673.
218. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994;19:278-282. (Pubitemid 24371047)
219. Desreumaux P, Ghosh S. Review article: Mode of action and delivery of 5-aminosalicylic acid -new evidence. Aliment Pharmacol Ther 2006;24 Suppl 1:2-9. (Pubitemid 44267773)
220. Brunner M, Assandri R, Kletter K, Tschurlovits M, Corrado ME, Villa R et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 2003;17:395-402. (Pubitemid 36259402)
221. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K et al. Randomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57:893-902. (Pubitemid 351919522)
222. Lakatos PL. Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun? World J Gastroenterol 2009;15:1799-1804.
223. McCormack PL, Robinson DM, Perry CM. Delayed-release Multi Matrix System (MMX) mesalazine: In ulcerative colitis. Drugs 2007;67:2635-2642. (Pubitemid 350159170)
224. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: Preliminary clinical findings for MMx. Inflamm Bowel Dis 2005; 11:421-427. (Pubitemid 40704075)
225. Krishnaiah YSR, Satyanarayana S, Prasad YVR, Rao SN. Evaluation of guar gum as a compression coat for drug targeting to colon. Int J Pharm 1998;171:137-146. (Pubitemid 29023106)